GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE143729 Query DataSets for GSE143729
Status Public on Mar 01, 2020
Title Antibiotic-induced microbiome perturbations are associated with significant alterations to colonic mucosal immunity in rhesus macaques
Organism Macaca mulatta
Experiment type Expression profiling by high throughput sequencing
Summary The diverse bacterial communities that colonize the gastrointestinal tract play an essential role in maintaining immune homeostasis through the production of critical metabolites such as short chain fatty acids (SCFA), and this can be disrupted by antibiotic use. However, few studies have addressed the effects of specific antibiotics longitudinally on the microbiome and immunity. We evaluated the effects of four specific antibiotics; enrofloxacin, cephalexin, paromomycin, and clindamycin; in healthy female rhesus macaques. All antibiotics disrupted the microbiome, including reduced abundances of fermentative bacteria and increased abundances of potentially pathogenic bacteria, including Enterobacteriaceae in stool, and decreased Helicobacteraceae in the colon. This was associated with decreased SCFAs, indicating altered bacterial metabolism. Importantly, antibiotic use also substantially altered local immune responses, including increased neutrophils and Th17 cells in the colon. Furthermore, we observed increased soluble-CD14 in plasma, indicating microbial translocation. These data provide a longitudinal evaluation of antibiotic-induced changes to the composition and function of colonic bacterial communities, associated with specific alterations in mucosal and systemic immunity.
Overall design 12 female rhesus macaques were treated with antibiotics (n=3/group) including: enrofloxacin (12 mg/kg, n=3, once daily, 9 days), cephalexin (30mg/kg, n=3, once daily, 9 days), paromomycin (25 mg/kg, n=3, twice daily, 9 days), or clindamycin (10 mg/kg, n=3, twice daily, 6 days). Total RNA was collected from biopsies of the colon before (42 and 21 days prior to treatment), during (day 3), and after (days 14, 28, 63 and 119 or 127) the antibiotic treatment for a total of 84 samples that were sequenced for comparing treatments longitudinally.
Contributor(s) Zevin A, Cheu R, Gustin A, Modesitt J, Hensley-McBain T, Manuzak J, Miller C, Coronado E, Gott T, Richardson B, Fang M, Cartwright M, Cartwright P, Wangari S, Agricola B, May D, Smith E, Gale M, Cameron C, Cameron M, Smedley J, Klatt N
Citation(s) 31797911
Submission date Jan 15, 2020
Last update date Mar 01, 2020
Contact name Mark Cameron
Organization name Case Western Reserve University
Department Population and Quantitative Health Sciences
Lab Cameron
Street address 10900 Euclid Ave
City Cleveland
State/province OH
ZIP/Postal code 44106
Country USA
Platforms (1)
GPL19129 Illumina HiSeq 2500 (Macaca mulatta)
Samples (84)
GSM4273229 Donor A15133 Treatment Enrofloxacin Day -42
GSM4273230 Donor A15133 Treatment Enrofloxacin Day -21
GSM4273231 Donor A15133 Treatment Enrofloxacin Day 3
BioProject PRJNA601454
SRA SRP242137

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE143729_normalizedCounts.csv.gz 11.7 Mb (ftp)(http) CSV
GSE143729_rawCounts.csv.gz 2.4 Mb (ftp)(http) CSV
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap